Comparative Pharmacology
Head-to-head clinical analysis: INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INPERSOL LC LM W DEXTROSE 1 5 IN PLASTIC CONTAINER versus INPERSOL LC LM W DEXTROSE 4 25 IN PLASTIC CONTAINER.
INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER vs INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inpersol-LC/LM with dextrose 1.5% is a peritoneal dialysis solution. The mechanism involves instillation into the peritoneal cavity, where dextrose creates an osmotic gradient that drives ultrafiltration of fluid and removal of uremic toxins (e.g., urea, creatinine) across the peritoneal membrane. The low calcium (LC) and low magnesium (LM) formulation helps prevent hypercalcemia and hypermagnesemia.
Removes uremic toxins and excess fluid via diffusion and ultrafiltration across the peritoneal membrane.
Intraperitoneal administration: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 1.5% dextrose solution into the peritoneal cavity via a permanent indwelling catheter. Exchange 4 times per day (every 6 hours) with a dwell time of 4-6 hours. For automated peritoneal dialysis (APD), typical regimen includes 2 liters per cycle with 4-5 cycles overnight and a daytime dwell.
Intraperitoneal: For continuous ambulatory peritoneal dialysis (CAPD), instill 2 liters of 4.25% dextrose solution into the peritoneal cavity four times daily (4 exchanges/day). For automated peritoneal dialysis (APD), use 2-3 liters per cycle with multiple cycles overnight. Adjust volume and frequency based on patient's fluid and electrolyte status.
None Documented
None Documented
Not applicable via systemic absorption; glucose absorbed from dialysate exhibits a terminal half-life of 1.5–2 hours in plasma, reflecting rapid cellular uptake and metabolism.
Dextrose: approximately 1-2 hours (terminal half-life of glucose in plasma); clinical context: continuous peritoneal dialysis (CAPD) maintains steady-state glucose levels.
Renal: negligible; primarily eliminated via peritoneal dialysis (dialysate outflow). Biliary/fecal: <1%.
Renal: 80-90% of dextrose metabolites (CO2 and H2O) are excreted via lungs and kidneys; electrolytes and water are eliminated renally. Biliary/fecal: minimal (<5%).
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution